Researchers from Leiden University Medical Center and Radboud University in the Netherlands have explored using genetically modified mosquitoes to deliver malaria vaccines. The approach uses a weakened Plasmodium falciparum parasite to induce immunity in participants without causing illness. In a clinical trial, participants were exposed to this parasite via mosquito bites. Two versions of the vaccine, GA1 and GA2, were developed and tested. The results, published in the New England Journal of Medicine, revealed 89% of those receiving the GA2 vaccine developed immunity, compared to 13% for the GA1 vaccine. There was a third group, given placebos. However, nobody in this group developed immunity. While promising, the small sample size of 20 participants necessitates larger trials. Experts caution that, while innovative, this method is impractical for widespread use and must be developed into a vialed vaccine for large-scale distribution.
SOURCE: AL JAZEERA
